Quinoline Compounds Inhibit Alpha5beta1 Integrin for Fibrosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrotic disorders, such as idiopathic pulmonary fibrosis and hepatic fibrosis, are ineffective as they target inflammation mechanisms, which are distinct from those involved in fibrogenesis, leading to unchecked tissue scarring and organ damage.
Innovation Solution
Development of quinoline compounds that inhibit alpha5beta1 integrin, a key player in fibroblast activation and extracellular matrix synthesis, to specifically target and reduce fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current anti-inflammatory treatments are used, then inflammation is reduced, but fibrosis and tissue scarring continue unchecked
Solution Approach 1:
The patent extracts the fibrosis-targeting function from general anti-inflammatory treatment by specifically inhibiting alpha5beta1 integrin, which is uniquely expressed in activated fibroblasts and myofibroblasts during fibrogenesis. This selective extraction allows treatment to address fibrosis without relying on non-specific anti-inflammatory mechanisms.
Solution Approach 2:
The patent introduces alpha5beta1 integrin as an intermediary target between inflammation and fibrosis. By blocking this integrin, which mediates fibroblast activation and extracellular matrix deposition, the therapy interrupts the pathogenic link between inflammatory stimuli and fibrotic outcomes.
2Strength
If inflammation mechanisms are targeted, then acute tissue damage is reduced, but chronic fibrotic scarring progresses
Solution Approach 1:
The patent applies preliminary action by inhibiting alpha5beta1 integrin before fibrotic scarring can fully develop. The integrin inhibitor prevents fibroblast activation and extracellular matrix deposition in advance, stopping the fibrotic process before it causes irreversible tissue damage and organ failure.
Solution Approach 2:
The patent ensures continuity of useful action by maintaining integrin inhibition throughout the fibrogenesis process. Continuous alpha5beta1 integrin blocking prevents intermittent fibrotic bursts and ensures sustained suppression of fibroblast proliferation and matrix deposition, preventing chronic scarring.
3Adaptability or versatility
If non-specific anti-inflammatory drugs are used, then general inflammation is suppressed, but fibroblast activation and matrix deposition remain unchecked
Solution Approach 1:
The patent applies local quality by designing an integrin inhibitor with high specificity for alpha5beta1 integrin, which is locally expressed in activated fibroblasts and myofibroblasts. This localized targeting ensures that fibrosis is inhibited precisely where needed, without the non-specific effects of general anti-inflammatory drugs.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific anti-inflammatory activity to specific integrin inhibition. By modifying the molecular target from general inflammatory pathways to alpha5beta1 integrin, the therapy achieves reliable fibrosis inhibition while maintaining safety profile.
Data Source
AI summary
A new medical therapy, and more particularly certain quinoline compounds which are anti-angiogenic integrin aplha5beta1 inhibitors, for use in the treatment of fibrosis, or a fibrosis-related disease, such as a fibrotic disease affecting the lung, liver, kidney, skin, epidermis, endodermis, muscle, tendon, cartilage, heart, stomach, large intestine, small intestine, colon, uterus, nervous system, testis, adrenal gland, artery, vein, biliary tract, or eye.